%0 Journal Article
%T Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.
%A Borque-Fernando Á
%A Zapatero A
%A Manneh R
%A Alonso-Gordoa T
%A Couñago F
%A Domínguez-Esteban M
%A López-Valcárcel M
%A Rodríguez-Antolín A
%A Sala-González N
%A Sanmamed N
%A Maroto P
%A  
%J Actas Urol Esp (Engl Ed)
%V 0
%N 0
%D 2024 May 11
%M 38740263
暂无%R 10.1016/j.acuroe.2024.05.008
%X The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). The selection of suitable patients for each therapeutic approach has become a determining factor to ensure efficacy and minimize side effects. This article combines recent clinical evidence with the accumulated experience of experts in medical oncology, radiation oncology and urology, to provide a comprehensive view and therapeutic recommendations for mHSPC.